The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy
Open accessAbstract
Purpose: After an initial response to androgen ablation, most prostate tumors recur, ultimately progressing to highly aggressive androgen-independent cancer. The molecular mechanisms underlying progression are not well known in part due to the rarity of androgen-independent samples from primary and metastatic sites. Experimental Design: We compared the gene expression profiles of 10 androgen-independent primary prostate tumor biopsies with 10 primary, untreated androgen-dependent tumors. Samples were laser capture microdissected, the RNA was amplified, and gene expression was assessed using Affymetrix Human Genome U133A GeneChip. Differential expression was examined with principal component analysis, hierarchical clustering, and Student's t testing. Analysis of gene ontology was done with Expression Analysis Systematic Explorer and gene expression data were integrated with genomic alterations with Differential Gene Locus Mapping. Results: Unsupervised principal component analysis showed that the androgen-dependent and androgen-independent tumors segregated from one another. After filtering the data, 239 differentially expressed genes were identified. Two main gene ontologies were found discordant between androgen-independent and androgen-dependent tumors: macromolecule biosynthesis was down-regulated and cell adhesion was up-regulated in androgen-independent tumors. Other differentially expressed genes were related to interleukin-6 signaling as well as angiogenesis, cell adhesion, apoptosis, oxidative stress, and hormone response. The Differential Gene Locus Mapping analysis identified nine regions of potential chromosomal deletion in the androgen-independent tumors, including 1p36, 3p21, 6p21, 8p21, 11p15, 11q12, 12q23, 16q12, and 16q21. Conclusions: Taken together, these data identify several unique characteristics of androgen-independent prostate cancer that may hold potential for the development of targeted therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Cited by
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer
Chakravarty, D., Sboner, A., Nair, S. S., Giannopoulou, E., Li, R., Hennig, S., Mosquera, J. M., Pauwels, J., Park, K., Kossai, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6383 · Cited by 621
Sharma, N. L., Massie, C. E., Ramos-Montoya, A., Zecchini, V., Scott, H. E., Lamb, A. D., MacArthur, S., Stark, R., Warren, A. Y., Mills, I. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.010 · Cited by 405
Zou, M., Toivanen, R., Mitrofanova, A., Floch, N., Hayati, S., Sun, Y., Le Magnen, C., Chester, D., Mostaghel, E. A., Califano, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1174 · Cited by 386
Metadata
- Authors
- Best, C. J. M., Gillespie, J. W., Yi, Y., Chandramouli, G. V. R., Perlmutter, M. A., Gathright, Y., Erickson, H. S., Georgevich, L., Tangrea, M. A., Duray, P. H., González, S., Velasco, A., Linehan, W. M., Matusik, R. J., Price, D. K., Figg, W. D., Emmert-Buck, M. R., & Chuaqui, R. F.
- Venue
- Clinical Cancer Research
- Published
- 2005-10-01
- Volume
- 11
- Issue
- 19
- Pages
- 6823-6834
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2168850532
- Cited by
- 186
- References
- 3
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-0585
- The paper
- Best, C. J. M., Gillespie, J. W., Yi, Y., Chandramouli, G. V. R., Perlmutter, M. A., Gathright, Y., Erickson, H. S., Georgevich, L., Tangrea, M. A., Duray, P. H., González, S., Velasco, A., Linehan, W. M., Matusik, R. J., Price, D. K., Figg, W. D., Emmert-Buck, M. R., & Chuaqui, R. F. (2005). Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-0585
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.